MARKET

RZLT

RZLT

Rezolute Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.400
0.000
0.00%
Closed 16:00 06/24 EDT
OPEN
3.420
PREV CLOSE
3.400
HIGH
3.470
LOW
3.355
VOLUME
134.64K
TURNOVER
237.09K
52 WEEK HIGH
17.39
52 WEEK LOW
2.260
MARKET CAP
114.18M
P/E (TTM)
-1.0787
1D
5D
1M
3M
1Y
5Y
Rezolute files for resale of 10.9M shares by selling stockholders
Rezolute (NASDAQ:RZLT) on Friday filed for resale of 10.9M shares by selling stockholders, issuable on the exercise of 10.9M class B warrants. The warrants have an exercise price of $0.001/share. RZLT
Seekingalpha · 06/17 21:14
BRIEF-Rezolute Inc Files Prospectus Relates To Resale Of 10.9 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
reuters.com · 06/17 21:07
BRIEF-Rezolute Says On June 16, Co Filed With Secretary Of State Of Nevada, A Certificate Of Amendment To Articles Of Incorporation Of Co
reuters.com · 06/17 12:37
Rezolute started at overweight at Cantor on potential of rare low blood sugar treatment
Cantor Fitzgerald has initiated Rezolute (NASDAQ:RZLT) at overweight citing the company's lead candidate RZ358 for congenital hyperinsulinism as it could be a more than $500M revenue generator by 2030. The
Seekingalpha · 06/15 16:12
Cantor Fitzgerald Starts Rezolute at Overweight With $9 Price Target
MT Newswires · 06/15 06:58
Short Volatility Alert: Rezolute, Inc.
On Tuesday, shares of Rezolute, Inc. (NASDAQ: RZLT) experienced volatile short activity. After the activity, the stock price went down -2.59% to $3.01.  The overall sentiment for RZLT has been Bearish.
Benzinga · 06/08 13:41
Rezolute GAAP EPS of -$0.65
Rezolute press release (NASDAQ:RZLT): Q3 GAAP EPS of -$0.65. Cash and cash equivalents totaled $63.4 million as of March 31, 2022
Seekingalpha · 05/12 21:21
--Oppenheimer Adjusts Rezolute Price Target to $23 From $25, Maintains Outperform Rating
MT Newswires · 05/10 10:27
More
No Data
Learn about the latest financial forecast of RZLT. Analyze the recent business situations of Rezolute Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RZLT stock price target is 15.60 with a high estimate of 23.00 and a low estimate of 8.00.
High23.00
Average15.60
Low8.00
Current 3.400
EPS
Actual
Estimate
-0.74-0.55-0.37-0.18
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 21
Institutional Holdings: 7.09M
% Owned: 21.10%
Shares Outstanding: 33.58M
TypeInstitutionsShares
Increased
7
232.02K
New
4
109.90K
Decreased
4
221.90K
Sold Out
6
564.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Director
Young-Jin Kim
Chief Executive Officer/Chief Financial Officer/Director
Nevan Elam
Co-Founder
Sankaram Mantripragada
Other
Brian Roberts
Independent Director
Philippe Fauchet
Independent Director
Wladimir Hogenhuis
Independent Director
Nerissa Kreher
Independent Director
Gilbert Labrucherie
No Data
No Data
About RZLT
Rezolute, Inc. is a clinical stage biopharmaceutical company developing drug therapies to improve the lives of patients with metabolic and orphan diseases. The Company's lead clinical asset, RZ358, is an antibody therapy in Phase II b development as a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder. Its second clinical asset, RZ402, is a selective and potent Plasma Kallikrein Inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of Diabetic Macular Edema (DME), is in Phase I development. The clinical study conducting by the Company is called RIZE - An open-label multiple-dose study of RZ358 in Patients with Congenital Hyperinsulinism.

Webull offers kinds of Rezolute Inc stock information, including NASDAQ:RZLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RZLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RZLT stock methods without spending real money on the virtual paper trading platform.